The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity

JR Kuchroo, DA Hafler, AH Sharpe, LE Lucca - Science immunology, 2021 - science.org
Immune checkpoint blockade has demonstrated success in treating cancer but can lead to
immune-related adverse events (irAEs), illustrating the centrality of these pathways in …
被引用次数：27 相关文章

The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity.

JR Kuchroo, DA Hafler, AH Sharpe… - Science Immunology, 2021 - europepmc.org
Immune checkpoint blockade has demonstrated success in treating cancer but can lead to
immune-related adverse events (irAEs), illustrating the centrality of these pathways in …

The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity

JR Kuchroo, DA Hafler, AH Sharpe… - Science …, 2021 - drive.google.com
Immune checkpoint blockade has demonstrated success in treating cancer but can lead to
immune-related adverse events (irAEs), illustrating the centrality of these pathways in …

The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity.

JR Kuchroo, DA Hafler, AH Sharpe… - Science …, 2021 - search.ebscohost.com
Immune checkpoint blockade has demonstrated success in treating cancer but can lead to
immune-related adverse events (irAEs), illustrating the centrality of these pathways in …

The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity

JR Kuchroo, DA Hafler, AH Sharpe… - Science …, 2021 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint blockade has demonstrated success in treating cancer but can lead to
immune-related adverse events (irAEs), illustrating the centrality of these pathways in …